Abstract
In this systematic review, we evaluated studies involving adjuvant and primary topical treatment for ocular surface squamous neoplasia (OSSN). The findings were: (i) adjuvant 5-fluorouracil (5-FU) reduces the risk of relapse after surgical excision with mild side effects [level Ib, grade of recommendation (GR) A]. (ii) Primary topical mitomycin (MMC) produces a high rate of complete response, low recurrence rate, and mild side effects (level Ib, GR A). (iii) Primary chemotherapy versus adjuvant chemotherapy produce similar rates of recurrence, with no significant difference (level IIb, GR B). (iv) Adjuvant 5-FU versus MMC showed no significant differences, with mild side effects in both groups and a better toxicity profile for MMC (level III, GR C). (v) Primary topical 5-FU versus MMC versus interferon (IFN) showed similar rates of tumor recurrence, mild side effects for all drugs, and more severe side effects in the 5-FU arm, followed successively by MMC and IFN (level III, GR C).
Highlights
Ocular surface squamous neoplasia (OSSN) is used to classify a broad spectrum of dysplastic changes involving the epithelia of the conjunctiva, cornea, and limbus[1]
In the last few decades, an increase in the incidence of OSSN has been observed in these countries, and this is mainly associated with sun exposure, human immunodeficiency virus (HIV), and human papillomavirus infection[4]
Side effects related to the treatment occurred more commonly in the 5-FU group, they were transient and mild
Summary
Ocular surface squamous neoplasia (OSSN) is used to classify a broad spectrum of dysplastic changes involving the epithelia of the conjunctiva, cornea, and limbus[1]. OSSN is a rare disease, with an incidence that ranges geogra phically (0.02 to 3.5 per 100,000); it is relatively common in Australia and African/tropical countries[2,3]. There is no data on the incidence of OSSN in Brazil; it is considered a rare disease in Brazil, it is still an important cause of ocular and systemic morbidity[1]. There are many treatment options for the management of OSSN, and selecting the most appropriate regime for a specific patient can minimize treatment-related morbidity and improve di sease control[5,6,7,8,9,10,11,12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
